KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Accumulated Expenses (2016 - 2022)

Gilead Sciences' Accumulated Expenses history spans 14 years, with the latest figure at $3.7 billion for Q3 2022.

  • For Q3 2022, Accumulated Expenses rose 9.09% year-over-year to $3.7 billion; the TTM value through Sep 2022 reached $3.7 billion, up 9.09%, while the annual FY2021 figure was $3.2 billion, 6.24% down from the prior year.
  • Accumulated Expenses reached $3.7 billion in Q3 2022 per GILD's latest filing, down from $4.1 billion in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $4.1 billion in Q3 2020 to a low of $2.3 billion in Q3 2018.
  • Average Accumulated Expenses over 5 years is $3.3 billion, with a median of $3.3 billion recorded in 2020.
  • Peak YoY movement for Accumulated Expenses: plummeted 33.27% in 2018, then skyrocketed 64.62% in 2019.
  • A 5-year view of Accumulated Expenses shows it stood at $3.1 billion in 2018, then fell by 2.07% to $3.1 billion in 2019, then grew by 12.56% to $3.5 billion in 2020, then fell by 6.24% to $3.2 billion in 2021, then grew by 13.26% to $3.7 billion in 2022.
  • Per Business Quant, the three most recent readings for GILD's Accumulated Expenses are $3.7 billion (Q3 2022), $4.1 billion (Q2 2022), and $3.5 billion (Q1 2022).